Stcube에스티큐브

Stcube remains deeply loss-making on ₩7.1B of trailing revenue, with its share price down over the past year.

On trailing twelve-month figures to H1 2026, Stcube reported revenue of ₩7.1B, an operating loss of ₩26.2B and a net loss of ₩24.1B. Cash stood at ₩18.6B against trailing free cash flow of -₩19.7B. The latest headlines, dated 14 October 2026, describe three development studies of nelmastobart presented at ESMO, but the company profile is not in the data, so the business model is not described beyond that.

What stands out

• Revenue fell 38.2% in 2025 to ₩7.0B, after a 93.9% jump in 2024 to ₩11.3B, so sales are volatile and small.
• Operating margin is about -368% on a trailing basis, and losses have been large in every year from 2021 to 2025.
• The stock closed at ₩6,980 on 13 October 2026, down 11.1% over one month and 6.6% over one year, and sits well above its 52-week low of ₩6,010 but far below its high of ₩22,500.
• Price-to-book is 7.9 and price-to-sales is 66.8, while P/E is not meaningful because earnings are negative.
• The sector label in the data is Retail & Trade, but the recent headlines concern an oncology drug candidate, and the data does not explain this difference.

What to watch

• The Q3 2026 quarterly report is not in the data, so the next update on revenue and cash burn is not yet confirmed.
• Cash of ₩18.6B versus trailing free cash flow of -₩19.7B suggests the company may need funding; the data does not say whether it has plans to raise capital.
• The fair value model gives a base of 33 and a bear case of 73 with a bull case of 0, which looks inconsistent and is not explained in the data, so it should not be relied on without checking the units and method.